These drugs have been shown to reduce the nuclear factor kappa‐light‐chain‐enhancer of activated B cells (NF‐kB)‐dependent signaling in cancer‐associated fibroblasts and to switch TAMs polarization through decreased proinflammatory cytokine production, keeping at bay protumorigenic cancer‐associated immune cells [143, 144]. Here, NFKB1 is linked to cancer.